Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial
HIV 감염에서 SARS-COV-2에 대한 Chadox1 NCOV-19 (AZD1222) 백신의 안전성 및 면역 원성 : 2/3 상 임상 시험의 단일 암 보체.
Clinical Trial
[키워드] ACHE
age
All participants
analysed
analyses
anti-Spike IgG
anti-spike IgG response
Anti-spike IgG responses
antibody
Antiretroviral therapy
ART
AstraZeneca
available data
AZD1222
CD4
CD4 cell
CD4 count
CD4 counts
Cell
cell-mediated immune response
Cell-mediated immune responses
cellular response
Cellular responses
ChAdOx1
ChAdOx1 nCoV-19
chill
chills
Clinical research
clinical trial
Coalition
Comorbidity
determined by
dose
Eligible participants
ELISA
ELISPOT
enrolled
enrolment
enzyme
enzyme-linked immunospot assay
fatigue
finding
FIVE
frequencies
Frequency
functional
funding
General population
headache
HIV
HIV clinics
HIV-negative
HIV-uninfected
humoral
Humoral response
humoral responses
IFN-γ
IgG response
IgG responses
immune responses
Immunity
immunogenic
immunogenicity
injection
injection site
Innovation
IQR
joint
joint pain
less
Live virus
Local
London
magnitude
malaise
male
median
median age
muscle ache
nausea
network
neutralisation
NIHR
NIHR Oxford Biomedical Research Centre
no correlation
no difference
occurred
Open-label
outcome
Oxford
Pain
participant
Participants
peaked
people with HIV
persistence
phase 2/3
phase 2/3 trial
plasma
Primary outcome
Primary outcomes
prime-boost regimen
proliferation
proliferative
protocol
reactogenicity
Registered
reported
required
response
Safe
Safety
SARS-CoV-2
SARS-CoV-2 spike-specific
Serious Adverse Event
Serious Adverse Events
single-arm
South
sustained
systemic reaction
systemic reactions
T-cell
the vaccine
undetectable
vaccination
Vaccine
vaccine immunogenicity
Valley
Viral
Viral load
were measured
with HIV
[DOI] 10.1016/S2352-3018(21)00103-X PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.1016/S2352-3018(21)00103-X PMC 바로가기 [Article Type] Clinical Trial